{
  "transcript_summary": "Johnson & Johnson reported strong 2025 results with $94.2 billion in revenue, driven by oncology and medtech, and provided guidance for 2026 revenue to reach $100 billion.",
  "total_claims_found": 28,
  "claims": [
    {
      "speaker_role": "ceo",
      "qualifiers": [
        "over"
      ],
      "claim_type": "absolute",
      "metric_context": "Total",
      "metric_type": "other",
      "gaap_classification": "unknown",
      "quote_end_char": 3746,
      "speaker": "Joaquin Duato",
      "quote_text": "In 2025, we invested over $32 billion in R&D and M&A, including the acquisitions of Intracellular Therapies and Halda Therapeutics.",
      "unit": "dollars",
      "quote_start_char": 3615,
      "period": "FY 2025",
      "claimed_value_raw": "$32 billion",
      "claim_id": "claim_001",
      "scale": "billions",
      "is_approximate": false,
      "confidence": 1,
      "claimed_value": 32
    },
    {
      "quote_end_char": 4201,
      "scale": "billions",
      "unit": "dollars",
      "confidence": 1,
      "quote_start_char": 4088,
      "metric_context": "Total",
      "quote_text": "Johnson & Johnson is the only healthcare company that will soon deliver more than $100 billion in annual revenue.",
      "claimed_value_raw": "$100 billion",
      "is_approximate": false,
      "claimed_value": 100,
      "period": "FY 2026",
      "claim_id": "claim_002",
      "claim_type": "guidance",
      "speaker_role": "ceo",
      "qualifiers": [
        "more than"
      ],
      "gaap_classification": "gaap",
      "speaker": "Joaquin Duato",
      "metric_type": "revenue"
    },
    {
      "metric_type": "revenue",
      "claim_type": "absolute",
      "unit": "count",
      "scale": "ones",
      "quote_text": "In fact, we now have 28 platform-sold products that generate at least $1 billion of revenue annually, and that makes our growth more sustainable.",
      "claimed_value_raw": "28",
      "period": "FY 2025",
      "speaker": "Joaquin Duato",
      "is_approximate": false,
      "quote_start_char": 4417,
      "speaker_role": "ceo",
      "quote_end_char": 4562,
      "claim_id": "claim_003",
      "confidence": 1,
      "gaap_classification": "gaap",
      "claimed_value": 28,
      "metric_context": "Total",
      "qualifiers": []
    },
    {
      "confidence": 1,
      "unit": "percent",
      "claimed_value_raw": "5.3%",
      "claim_type": "yoy_growth",
      "comparison_period": "FY 2024",
      "metric_type": "revenue",
      "period": "FY 2025",
      "gaap_classification": "non_gaap",
      "is_approximate": false,
      "qualifiers": [
        "operational"
      ],
      "quote_text": "Turning to our results, over the full year, we delivered 5.3% operational sales growth.",
      "claim_id": "claim_004",
      "scale": "ones",
      "quote_end_char": 4782,
      "claimed_value": 5.3,
      "quote_start_char": 4695,
      "speaker": "Joaquin Duato",
      "speaker_role": "ceo",
      "metric_context": "Total"
    },
    {
      "metric_context": "Innovative Medicine",
      "speaker": "Joaquin Duato",
      "claimed_value_raw": "5.3%",
      "unit": "percent",
      "comparison_period": "FY 2024",
      "scale": "ones",
      "quote_start_char": 4957,
      "quote_text": "In innovative medicine, we reported operational sales growth for the year of 5.3%.",
      "is_approximate": false,
      "period": "FY 2025",
      "confidence": 1,
      "quote_end_char": 5039,
      "speaker_role": "ceo",
      "claim_id": "claim_005",
      "qualifiers": [
        "reported operational sales growth"
      ],
      "claimed_value": 5.3,
      "metric_type": "revenue",
      "claim_type": "yoy_growth",
      "gaap_classification": "non_gaap"
    },
    {
      "is_approximate": false,
      "gaap_classification": "gaap",
      "speaker": "Joaquin Duato",
      "quote_start_char": 5040,
      "unit": "dollars",
      "claimed_value": 60,
      "metric_context": "Pharmaceutical",
      "qualifiers": [
        "exceeded"
      ],
      "claim_id": "claim_006",
      "quote_text": "Full-year sales for our Pharmaceutical business exceeded $60 billion for the first time, with 13 brands growing double digits.",
      "scale": "billions",
      "period": "FY 2025",
      "confidence": 1,
      "claimed_value_raw": "$60 billion",
      "metric_type": "revenue",
      "quote_end_char": 5166,
      "claim_type": "absolute",
      "speaker_role": "ceo"
    },
    {
      "is_approximate": false,
      "scale": "ones",
      "quote_text": "In oncology, in 2025, we delivered 21% operational sales growth, and we expect to exceed $50 billion in annual sales by 2030.",
      "unit": "percent",
      "claim_type": "yoy_growth",
      "speaker": "Joaquin Duato",
      "gaap_classification": "non_gaap",
      "speaker_role": "ceo",
      "quote_start_char": null,
      "quote_end_char": null,
      "period": "FY 2025",
      "confidence": 1,
      "claim_id": "claim_007",
      "claimed_value": 21,
      "metric_type": "revenue",
      "claimed_value_raw": "21%",
      "metric_context": "Oncology",
      "qualifiers": [
        "operational sales growth"
      ],
      "comparison_period": "FY 2024"
    },
    {
      "claim_id": "claim_008",
      "quote_start_char": null,
      "quote_end_char": null,
      "quote_text": "In oncology, in 2025, we delivered 21% operational sales growth, and we expect to exceed $50 billion in annual sales by 2030.",
      "claimed_value": 50,
      "confidence": 1,
      "qualifiers": [
        "expect to exceed"
      ],
      "gaap_classification": "gaap",
      "speaker_role": "ceo",
      "scale": "billions",
      "unit": "dollars",
      "claimed_value_raw": "$50 billion",
      "period": "FY 2030",
      "is_approximate": false,
      "speaker": "Joaquin Duato",
      "metric_type": "revenue",
      "claim_type": "guidance",
      "metric_context": "Oncology"
    },
    {
      "unit": "dollars",
      "claim_type": "absolute",
      "qualifiers": [
        "over"
      ],
      "quote_text": "With annual sales over $14 billion, DARZALEX grew an impressive 22% across the full year.",
      "period": "FY 2025",
      "claimed_value_raw": "$14 billion",
      "is_approximate": false,
      "speaker_role": "ceo",
      "claim_id": "claim_009",
      "metric_context": "DARZALEX",
      "scale": "billions",
      "quote_end_char": 6241,
      "confidence": 1,
      "metric_type": "revenue",
      "quote_start_char": 6152,
      "claimed_value": 14,
      "speaker": "Joaquin Duato",
      "gaap_classification": "gaap"
    },
    {
      "claimed_value_raw": "57%",
      "quote_start_char": 8825,
      "claim_type": "yoy_growth",
      "qualifiers": [],
      "comparison_period": "FY 2024",
      "scale": "ones",
      "is_approximate": false,
      "claimed_value": 57,
      "speaker_role": "ceo",
      "quote_text": "Spravato continues its strong trajectory with 57% growth in the year, with more than two hundred thousand patients now treated worldwide.",
      "speaker": "Joaquin Duato",
      "confidence": 1,
      "claim_id": "claim_011",
      "metric_context": "Spravato",
      "unit": "percent",
      "gaap_classification": "gaap",
      "metric_type": "revenue",
      "quote_end_char": 8962,
      "period": "FY 2025"
    },
    {
      "qualifiers": [
        "operational sales for the year grew"
      ],
      "claimed_value": 5.4,
      "scale": "ones",
      "claim_id": "claim_012",
      "period": "FY 2025",
      "quote_start_char": null,
      "confidence": 1,
      "quote_end_char": null,
      "is_approximate": false,
      "comparison_period": "FY 2024",
      "speaker_role": "ceo",
      "speaker": "Joaquin Duato",
      "metric_context": "MedTech",
      "gaap_classification": "non_gaap",
      "quote_text": "Turning to MedTech, where operational sales for the year grew 5.4%.",
      "metric_type": "revenue",
      "claimed_value_raw": "5.4%",
      "unit": "percent",
      "claim_type": "yoy_growth"
    },
    {
      "unit": "dollars",
      "period": "FY 2025",
      "claimed_value": 4,
      "gaap_classification": "gaap",
      "metric_type": "revenue",
      "confidence": 1,
      "claim_type": "absolute",
      "is_approximate": true,
      "quote_start_char": 9231,
      "metric_context": "MedTech",
      "scale": "billions",
      "claim_id": "claim_013",
      "qualifiers": [
        "nearly"
      ],
      "claimed_value_raw": "$4 billion",
      "speaker_role": "ceo",
      "quote_text": "In 2025, we delivered nearly $4 billion in sales, with strong performance in cardiovascular and accelerating momentum across surgery and vision.",
      "quote_end_char": 9375,
      "speaker": "Joaquin Duato"
    },
    {
      "quote_start_char": 9591,
      "claimed_value": 15,
      "unit": "percent",
      "gaap_classification": "non_gaap",
      "confidence": 1,
      "claim_type": "yoy_growth",
      "metric_context": "Cardiovascular",
      "scale": "ones",
      "is_approximate": false,
      "comparison_period": "FY 2024",
      "claim_id": "claim_014",
      "quote_text": "Johnson & Johnson today is a leader in three cardiovascular segments, with the portfolio delivering 15% operational sales growth in the year.",
      "qualifiers": [
        "operational sales growth"
      ],
      "claimed_value_raw": "15%",
      "period": "FY 2025",
      "speaker_role": "ceo",
      "quote_end_char": 9732,
      "speaker": "Joaquin Duato",
      "metric_type": "revenue"
    },
    {
      "quote_text": "And finally, vision, which delivered robust annual operational sales growth of 5.3% with particularly strong momentum in surgical vision.",
      "metric_context": "Vision",
      "claimed_value_raw": "5.3%",
      "claim_id": "claim_016",
      "period": "FY 2025",
      "scale": "ones",
      "comparison_period": "FY 2024",
      "is_approximate": false,
      "quote_end_char": 11392,
      "speaker_role": "ceo",
      "unit": "percent",
      "gaap_classification": "non_gaap",
      "claim_type": "yoy_growth",
      "metric_type": "revenue",
      "speaker": "Joaquin Duato",
      "quote_start_char": 11255,
      "claimed_value": 5.3,
      "qualifiers": [
        "robust annual operational sales growth"
      ],
      "confidence": 1
    },
    {
      "is_approximate": false,
      "claim_id": "claim_017",
      "claimed_value_raw": "$24.6 billion",
      "qualifiers": [
        "Worldwide sales"
      ],
      "quote_end_char": 12320,
      "period": "Q4 2025",
      "speaker_role": "management",
      "quote_text": "Worldwide sales were $24.6 billion for the quarter.",
      "metric_type": "revenue",
      "claimed_value": 24.6,
      "speaker": "Darren Snellgrove",
      "confidence": 1,
      "gaap_classification": "gaap",
      "claim_type": "absolute",
      "metric_context": "Total",
      "unit": "dollars",
      "scale": "billions",
      "quote_start_char": 12269
    },
    {
      "gaap_classification": "gaap",
      "claimed_value_raw": "7.1%",
      "claim_type": "yoy_growth",
      "metric_type": "revenue",
      "quote_text": "Sales increased 7.1% despite an approximate 650 basis point headwind from STELARA.",
      "metric_context": "Total",
      "claimed_value": 7.1,
      "speaker": "Darren Snellgrove",
      "unit": "percent",
      "scale": "ones",
      "quote_end_char": 12404,
      "period": "Q4 2025",
      "speaker_role": "management",
      "quote_start_char": 12322,
      "confidence": 1,
      "comparison_period": "Q4 2024",
      "claim_id": "claim_018",
      "qualifiers": [],
      "is_approximate": false
    },
    {
      "quote_end_char": 12746,
      "scale": "billions",
      "period": "Q4 2025",
      "metric_context": "Total",
      "speaker_role": "management",
      "is_approximate": false,
      "claim_id": "claim_019",
      "claimed_value_raw": "$5.1 billion",
      "confidence": 1,
      "claim_type": "absolute",
      "qualifiers": [
        "net earnings"
      ],
      "quote_start_char": 12633,
      "metric_type": "net_income",
      "claimed_value": 5.1,
      "speaker": "Darren Snellgrove",
      "unit": "dollars",
      "gaap_classification": "gaap",
      "quote_text": "For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $2.1 versus $1.41 a year ago."
    },
    {
      "is_approximate": false,
      "speaker_role": "management",
      "confidence": 1,
      "quote_text": "For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $2.1 versus $1.41 a year ago.",
      "claim_id": "claim_020",
      "quote_start_char": 12633,
      "period": "Q4 2025",
      "claimed_value": 2.1,
      "claimed_value_raw": "$2.1",
      "metric_type": "eps_diluted",
      "qualifiers": [
        "diluted earnings per share was $2.1 versus $1.41 a year ago."
      ],
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap",
      "claim_type": "absolute",
      "scale": null,
      "quote_end_char": 12746,
      "unit": "per_share",
      "metric_context": "Total"
    },
    {
      "scale": "billions",
      "speaker_role": "management",
      "period": "Q4 2025",
      "quote_start_char": 12748,
      "is_approximate": false,
      "claim_id": "claim_021",
      "confidence": 1,
      "qualifiers": [
        "Adjusted net earnings"
      ],
      "claimed_value_raw": "$6 billion",
      "gaap_classification": "non_gaap",
      "metric_type": "net_income",
      "claim_type": "absolute",
      "metric_context": "Total",
      "unit": "dollars",
      "quote_text": "Adjusted net earnings for the quarter were $6 billion, and adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024.",
      "speaker": "Darren Snellgrove",
      "quote_end_char": 12904,
      "claimed_value": 6
    },
    {
      "speaker_role": "management",
      "quote_start_char": 12748,
      "confidence": 1,
      "quote_text": "Adjusted net earnings for the quarter were $6 billion, and adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024.",
      "claimed_value_raw": "21.5%",
      "gaap_classification": "non_gaap",
      "unit": "percent",
      "qualifiers": [
        "adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024."
      ],
      "quote_end_char": 12904,
      "comparison_period": "Q4 2024",
      "claim_type": "yoy_growth",
      "speaker": "Darren Snellgrove",
      "period": "Q4 2025",
      "metric_type": "eps_diluted",
      "metric_context": "Total",
      "is_approximate": false,
      "scale": "ones",
      "claimed_value": 21.5,
      "claim_id": "claim_022"
    },
    {
      "unit": "dollars",
      "confidence": 1,
      "claim_id": "claim_023",
      "speaker_role": "management",
      "quote_text": "For the full year 2025, worldwide sales were $94.2 billion.",
      "is_approximate": false,
      "period": "FY 2025",
      "metric_type": "revenue",
      "claimed_value_raw": "$94.2 billion",
      "quote_start_char": 13071,
      "gaap_classification": "gaap",
      "claimed_value": 94.2,
      "speaker": "Darren Snellgrove",
      "claim_type": "absolute",
      "metric_context": "Total",
      "quote_end_char": 13130,
      "qualifiers": [
        "worldwide sales"
      ],
      "scale": "billions"
    },
    {
      "gaap_classification": "non_gaap",
      "speaker": "Darren Snellgrove",
      "claim_type": "yoy_growth",
      "metric_context": "Total",
      "qualifiers": [
        "adjusted diluted earnings per share was $10.79, both representing an increase of 8.1% compared to full year 2024."
      ],
      "quote_end_char": 14031,
      "scale": "ones",
      "unit": "percent",
      "speaker_role": "management",
      "comparison_period": "FY 2024",
      "confidence": 1,
      "claim_id": "claim_024",
      "is_approximate": false,
      "period": "FY 2025",
      "quote_text": "Full-year 2025 adjusted net earnings were $26.2 billion, and adjusted diluted earnings per share was $10.79, both representing an increase of 8.1% compared to full year 2024.",
      "claimed_value": 8.1,
      "quote_start_char": 13857,
      "claimed_value_raw": "8.1%",
      "metric_type": "eps_diluted"
    },
    {
      "claimed_value": 19.7,
      "claim_id": "claim_025",
      "speaker": "Joe Wolk",
      "quote_text": "The company generated $19.7 billion of free cash flow during 2025, on par with 2024 despite increased capital investment in the US and the impact of tariffs.",
      "period": "FY 2025",
      "metric_context": "Total",
      "claimed_value_raw": "$19.7 billion",
      "gaap_classification": "unknown",
      "speaker_role": "cfo",
      "unit": "dollars",
      "metric_type": "free_cash_flow",
      "is_approximate": false,
      "qualifiers": [],
      "scale": "billions",
      "quote_end_char": 22216,
      "confidence": 1,
      "claim_type": "absolute",
      "quote_start_char": 22059
    },
    {
      "claim_id": "claim_026",
      "unit": "dollars",
      "metric_context": "Total",
      "scale": "billions",
      "is_approximate": true,
      "claimed_value_raw": "$21 billion",
      "period": "FY 2026",
      "quote_text": "As we move forward in 2026, we expect to elevate free cash flow generation to approximately $21 billion.",
      "gaap_classification": "unknown",
      "claimed_value": 21,
      "qualifiers": [
        "approximately"
      ],
      "quote_start_char": 22350,
      "confidence": 1,
      "quote_end_char": 22454,
      "speaker_role": "cfo",
      "metric_type": "free_cash_flow",
      "claim_type": "guidance",
      "speaker": "Joe Wolk"
    },
    {
      "period": "FY 2026",
      "qualifiers": [
        "midpoint of $100 billion"
      ],
      "quote_text": "We anticipate operational sales growth in the range of 5.7% to 6.7% with a midpoint of $100 billion or 6.2%.",
      "unit": "percent",
      "quote_start_char": 22677,
      "claim_type": "guidance",
      "metric_type": "revenue",
      "speaker": "Joe Wolk",
      "scale": "ones",
      "quote_end_char": 22785,
      "metric_context": "Total",
      "claim_id": "claim_027",
      "claimed_value": 6.2,
      "claimed_value_raw": "6.2%",
      "gaap_classification": "non_gaap",
      "speaker_role": "cfo",
      "confidence": 1,
      "is_approximate": false
    },
    {
      "qualifiers": [
        "midpoint for a range of $11.28 to $11.48."
      ],
      "quote_text": "Turning to adjusted operational earnings per share, we expect growth of 5.5% at the midpoint for a range of $11.28 to $11.48.",
      "quote_end_char": 25192,
      "scale": "ones",
      "gaap_classification": "non_gaap",
      "claimed_value": 5.5,
      "period": "FY 2026",
      "claim_id": "claim_028",
      "speaker_role": "cfo",
      "is_approximate": false,
      "quote_start_char": 25067,
      "claimed_value_raw": "5.5%",
      "confidence": 1,
      "metric_context": "Total",
      "claim_type": "guidance",
      "metric_type": "eps_diluted",
      "speaker": "Joe Wolk",
      "unit": "percent"
    },
    {
      "qualifiers": [
        "approximately"
      ],
      "period": "Q4 2025",
      "comparison_period": "Q4 2024",
      "is_approximate": true,
      "quote_text": "Abiomed and Shockwave performed particularly well, delivering operational growth of approximately 1823% in the quarter.",
      "quote_start_char": 9733,
      "claim_id": "claim_015",
      "metric_context": "Abiomed and Shockwave",
      "unit": "percent",
      "confidence": 0.8,
      "speaker": "Joaquin Duato",
      "claim_type": "yoy_growth",
      "speaker_role": "ceo",
      "claimed_value": 1823,
      "quote_end_char": 9852,
      "metric_type": "revenue",
      "scale": "ones",
      "gaap_classification": "non_gaap",
      "claimed_value_raw": "1823%"
    }
  ],
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 4,
  "extracted_at": "2026-02-13T17:36:21.513090"
}